Premium
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Author(s) -
Min Yuanzeng,
Mao ChengQiong,
Chen Siming,
Ma Guolin,
Wang Jun,
Liu Yangzhong
Publication year - 2012
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201201562
Subject(s) - prodrug , cisplatin , platinum , conjugate , chemistry , drug resistance , drug delivery , endocytosis , drug , pharmacology , cancer research , biochemistry , medicine , biology , chemotherapy , organic chemistry , genetics , catalysis , mathematical analysis , mathematics , cell
Resistance is futile : A platinum(IV) prodrug conjugated to a gold‐nanorod‐based delivery agent avoids the type of drug resistance that is associated with cisplatin (see picture). This conjugate is taken up into cells through endocytosis, thus avoiding the resistance‐associated uptake mediated by the copper transport protein Ctr1. The platinum(IV) prodrug is more inert than cisplatin to glutathione and metallothionein, which cause deactivation.